110 related articles for article (PubMed ID: 20570953)
1. Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration.
Weir GC; Bonner-Weir S
Endocrinology; 2010 Jul; 151(7):2971-3. PubMed ID: 20570953
[No Abstract] [Full Text] [Related]
2. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
[TBL] [Abstract][Full Text] [Related]
3. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
4. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
5. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
6. Incretin therapy and beta cell function.
Goundan PN; Underwood P; Mantzoros CS
Metabolism; 2015 Feb; 64(2):157-9. PubMed ID: 25456457
[No Abstract] [Full Text] [Related]
7. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
9. New treatments for type 2 diabetes--the DPP4 inhibitors.
Gadsby R
Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
11. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Zhao Y; Yang L; Wang X; Zhou Z
Diabetes Metab Res Rev; 2014 Nov; 30(8):646-53. PubMed ID: 24446278
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
Wu YJ; Guo X; Li CJ; Li DQ; Zhang J; Yang Y; Kong Y; Guo H; Liu DM; Chen LM
Metabolism; 2015 Feb; 64(2):226-35. PubMed ID: 25195070
[TBL] [Abstract][Full Text] [Related]
13. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Ding L; Gysemans CA; Stangé G; Heremans Y; Yuchi Y; Takiishi T; Korf H; Chintinne M; Carr RD; Heimberg H; Pipeleers D; Mathieu C
PLoS One; 2014; 9(9):e107935. PubMed ID: 25268801
[TBL] [Abstract][Full Text] [Related]
14. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Cabrera SM; Colvin SC; Tersey SA; Maier B; Nadler JL; Mirmira RG
Clin Exp Immunol; 2013 Jun; 172(3):375-82. PubMed ID: 23600825
[TBL] [Abstract][Full Text] [Related]
15. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
[TBL] [Abstract][Full Text] [Related]
16. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Sato K; Nakamura A; Shirakawa J; Muraoka T; Togashi Y; Shinoda K; Orime K; Kubota N; Kadowaki T; Terauchi Y
Endocrinology; 2012 Mar; 153(3):1093-102. PubMed ID: 22315446
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
18. [Vildagliptin].
Iwamoto Y
Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
[No Abstract] [Full Text] [Related]
19. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
20. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
[Next] [New Search]
